[[Beta blocker]]s help patients with cardiovascular disease by blocking β receptors, while many of the side-effects of these medications are caused by their blockade of β2 receptors.<ref name="pmid10453968 ">{{cite journal |vauthors=Tafreshi MJ, Weinacker AB |title=Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma |journal=Pharmacotherapy |volume=19 |issue=8 |pages=974–8 |date=August 1999 |pmid=10453968 |doi= 10.1592/phco.19.11.974.31575|url=}}</ref> For this reason, beta blockers that selectively block β1 [[adrenergic receptor]]s (termed cardioselective or β1-selective beta blockers) produce fewer adverse effects (for instance, bronchoconstriction) than those drugs that non-selectively block both β1 and β2 receptors.

 
Nebivolol is unique as a beta-blocker.<ref name="pmid17521213">{{cite journal |vauthors=Agabiti Rosei E, Rizzoni D |title=Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics |journal=Drugs |volume=67 |issue=8 |pages=1097–107 |year=2007 |pmid=17521213 |doi= 10.2165/00003495-200767080-00001|url=}}</ref> Unlike carvedilol, it has a [[nitric oxide]] (NO)-potentiating, vasodilatory effect via stimulation of β3 receptors.<ref>{{cite journal|last1=Galougahi|first1=Keyvan|title=β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia|journal=JAHA|date=February 19, 2016|doi=10.1161/JAHA.115.002824|url=http://jaha.ahajournals.org/content/5/2/e002824}}</ref><ref name="pmid17326335">{{cite journal |author=Weiss R |title=Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation |journal=Vasc Health Risk Manag |volume=2 |issue=3 |pages=303–8 |year=2006 |pmid=17326335 |pmc=1993984 |doi= 10.2147/vhrm.2006.2.3.303|url=}}</ref><ref name="pmid19454898">{{cite journal |author=Bakris G |title=An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade |journal=J. Cardiovasc. Pharmacol. |volume=53 |issue=5 |pages=379–87 |date=May 2009 |pmid=19454898 |doi=10.1097/FJC.0b013e31819fd501 |url=}}</ref> Along with [[labetalol]], [[celiprolol]] and [[carvedilol]], it is one of four beta blockers to cause dilation of blood vessels in addition to effects on the heart.<ref name="pmid19454898" /> However, recent studies question the clinical relevance of this property to Nebivolol's efficacy.<ref name="npsradar001">{{cite web |url=http://www.nps.org.au/health_professionals/publications/nps_radar/2010/march_2010/nebivolol |title=Nebivolol (Nebilet) for chronic heart failure |author=National Prescribing Service |date=1 March 2010 |accessdate=12 March 2010}}</ref>

 
Nebivolol lowers blood pressure (BP) by reducing [[peripheral vascular resistance]], and significantly increases [[stroke volume]] with preservation of cardiac output.<ref name="pmid12888152">{{cite journal |vauthors=Kamp O, Sieswerda GT, Visser CA |title=Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension |journal=Am. J. Cardiol. |volume=92 |issue=3 |pages=344–8 |date=August 2003 |pmid=12888152 |doi= 10.1016/S0002-9149(03)00645-3|url=}}</ref> The net hemodynamic effect of nebivolol is the result of a balance between the depressant effects of beta-blockade and an action that maintains cardiac output.<ref name="pmid16961165">{{cite journal |vauthors=Gielen W, Cleophas TJ, Agrawal R |title=Nebivolol: a review of its clinical and pharmacological characteristics |journal=Int J Clin Pharmacol Ther |volume=44 |issue=8 |pages=344–57 |date=August 2006 |pmid=16961165 |doi= 10.5414/cpp44344|url=}}</ref> Antihypertensive responses were significantly higher with nebivolol than with placebo in trials enrolling patient groups considered representative of the U.S. hypertensive population, in Black patients, and in those receiving concurrent treatment with other antihypertensive drugs.<ref name="test">Baldwin CM, Keam SJ. Nebivolol: In the Treatment of Hypertension in the US. ''Am J Cardiovasc Drugs'' 2009; 9 (4): 253-260. [http://adisonline.com/cardiovascular/pages/articleviewer.aspx?year=2009&issue=09040&article=00004&type=abstract Link text]</ref>

 
===Pharmacology of side-effects===

 
Several studies have suggested that nebivolol has reduced typical beta-blocker-related side effects, such as [[fatigue (medical)|fatigue]], [[clinical depression]], [[bradycardia]], or [[impotence]].<ref name="pmid11811391">{{cite journal |author=Pessina AC |title=Metabolic effects and safety profile of nebivolol |journal=J. Cardiovasc. Pharmacol. |volume=Suppl 3 |issue= |pages=S33–5 |series=38 |date=December 2001 |pmid=11811391 |doi= |url=}}</ref><ref name="pmid16373195">{{cite journal |author=Weber MA |title=The role of the new beta-blockers in treating cardiovascular disease |journal=Am. J. Hypertens. |volume=18 |issue=12 Pt 2 |pages=169S–176S |date=December 2005 |pmid=16373195 |doi=10.1016/j.amjhyper.2005.09.009 |url=}}</ref><ref name="pmid11518851">{{cite journal |vauthors=Poirier L, Cléroux J, Nadeau A, Lacourcière Y |title=Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients |journal=J. Hypertens. |volume=19 |issue=8 |pages=1429–35 |date=August 2001 |pmid=11518851 |doi= 10.1097/00004872-200108000-00011|url=}}</ref> However, according to the [[Food and Drug Administration (United States)|FDA]]<ref name="Thomas Abrams 2008">{{cite web |title=Warning Letter |url=http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054010.pdf |format=PDF |author=Thomas Abrams |date=2008-08-28 |publisher=Food and Drug Administration |accessdate=2008 |quote=FDA is not aware of any substantial evidence or substantial clinical experience that demonstrates that Bystolic represents a 'novel' or 'next generation' beta blocker for the treatment of hypertension. Indeed, we are not aware of any well-designed trials comparing Bystolic to other β-blockers. Furthermore, FDA is not aware of any data that would render Bystolic's mechanism of action 'unique.'}}</ref>
